journal article·2023-12Open access

An Adjustable Adjuvant STINGsome for Tailoring the Potent and Broad Immunity Against SARS‐CoV‐2 and Monkeypox Virus via STING and Necroptosis

Jun‐Jun Wu, Guan‐Jie Chen, Chen‐Yuan Fan, Fan Shen, Yi Yang, Wei Pang, Zhen‐Nan Zhao, Hong‐Xin Guan, Huan Wu, Ying Lu, Ya‐Juan Fu, Qi Chen, Yong‐Tang Zheng, Songying Ouyang

Advanced Functional Materials· Volume 33· Issue 50

Abstract

Abstract The pandemics induced by emerging SARS‐CoV‐2 variants and monkeypox virus infection have triggered the urgent need for broad‐spectrum vaccines. Except for “super” antigen designs, pattern recognition receptor (PRR) agonist‐based adjuvants might blaze a new trail, through enhancing the immune response of conserved antigen epitopes shared among variants for cross‐protection. Ideal adjuvants with proper adjustments could be conveniently applied to different antigens and antigen types in response to new pandemics. However, general strategies for modulating PRR agonist‐based adjuvant properties to tailor the optimal immunity remain to be further explored. Here, an adjuvant platform STINGsome is described, composed of a STING agonist and pH‐switchable IP9 liposomes, to simulate viral infection via STING activation and necroptosis. STINGsomes function as an efficient adjuvant to elicit broad and potent immune responses against multiple SARS‐CoV‐2 VOCs (Omicron BA.1, BA.2, BA.3, BA.4/5) and a monkeypox virus. More importantly, the adjuvant properties of STINGsomes can be tuned by simply adjusting the IP9 percentage, owing to distinct kinetics from local release to lymph node stimulation. Thus, this study provides a relatively simple strategy to adapt an adjuvant platform to different pathogenic antigens, ultimately achieving optimal protective responses.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: interferon and immune responses · Viral Infections and Outbreaks Research · Viral Infections and Vectors

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Microbial Pathogenesis and Interventions of Fujian Province University the Key Laboratory of Innate Immune Biology of Fujian Province Biomedical Research Center of South China Key Laboratory of OptoElectronic Science and Technology for Medicine of the Ministry of Education College of Life Sciences Fujian Normal University 350117 Fuzhou China

Key Laboratory of Bioactive Peptides of Yunnan Province/Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences Center for Biosafety Mega‐Science Kunming Institute of Zoology Chinese Academy of Sciences Kunming Yunnan 650223 China

University of Chinese Academy of Sciences 100049 Beijing China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Natural Science Foundation of Fujian Province

References (35)

Show source-provided references
1. Cao Y. · Nature · 2023 · 614 · 521
2. 10.1016/j.cell.2022.06.00510.1016/j.cell.2022.06.005 ↗
3. 10.1038/s41577-022-00775-410.1038/s41577-022-00775-4 ↗
4. 10.1038/s41422-023-00792-510.1038/s41422-023-00792-5 ↗
5. 10.1002/jmv.2814310.1002/jmv.28143 ↗
6. 10.1126/science.aau081010.1126/science.aau0810 ↗
7. Yin Q. · Nat. Mater. · 2023 · 22 · 380
8. 10.1021/acs.chemrev.9b0083310.1021/acs.chemrev.9b00833 ↗
9. 10.1021/acs.accounts.2c0036010.1021/acs.accounts.2c00360 ↗
10. 10.1039/D2CS00486K10.1039/D2CS00486K ↗
11. 10.1016/j.cell.2020.08.01710.1016/j.cell.2020.08.017 ↗
12. 10.1126/sciimmunol.abi900210.1126/sciimmunol.abi9002 ↗
13. 10.1126/sciimmunol.abi900710.1126/sciimmunol.abi9007 ↗
14. 10.1002/med.2164910.1002/med.21649 ↗
15. 10.1002/asia.20210140010.1002/asia.202101400 ↗
16. 10.1007/s12274-022-4282-x10.1007/s12274-022-4282-x ↗
17. 10.1007/s12274-021-4012-910.1007/s12274-021-4012-9 ↗
18. 10.31635/ccschem.023.20230275110.31635/ccschem.023.202302751 ↗
19. 10.1038/s41392-023-01557-710.1038/s41392-023-01557-7 ↗
20. 10.1038/s12276-021-00634-710.1038/s12276-021-00634-7 ↗
21. 10.1038/s41418-018-0172-x10.1038/s41418-018-0172-x ↗
22. 10.1016/j.tim.2021.11.01110.1016/j.tim.2021.11.011 ↗
23. 10.1038/s41392-020-00334-010.1038/s41392-020-00334-0 ↗
24. 10.1038/s41573-021-00163-y10.1038/s41573-021-00163-y ↗
25. 10.1038/s41563-020-00886-010.1038/s41563-020-00886-0 ↗
26. 10.31635/ccschem.022.20220185910.31635/ccschem.022.202201859 ↗
27. 10.1039/D0CC06959K10.1039/D0CC06959K ↗
28. 10.1039/C8CC04860F10.1039/C8CC04860F ↗
29. 10.7554/eLife.5268710.7554/eLife.52687 ↗
30. 10.1126/sciadv.abe581910.1126/sciadv.abe5819 ↗
31. 10.1016/j.cell.2020.09.03810.1016/j.cell.2020.09.038 ↗
32. 10.1038/s41422-022-00746-310.1038/s41422-022-00746-3 ↗
33. 10.1128/JVI.01504-2110.1128/JVI.01504-21 ↗
34. 10.1016/j.immuni.2019.08.00510.1016/j.immuni.2019.08.005 ↗
35. 10.1016/j.cell.2022.01.00910.1016/j.cell.2022.01.009 ↗